182 results on '"Bachmeier, Christina A"'
Search Results
2. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
3. Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy
4. Table S5 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
5. Data from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
6. Figure S2 from Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
7. Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma
8. Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration
9. Abstract 10475: Serial Inflammatory Cytokine Levels Are Increased in Atrial Fibrillation After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
10. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma
11. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma
12. Cytokine Release Syndrome and Other Toxicities Associated With Novel Cellular Therapies
13. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis
14. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
15. Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities
16. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma
17. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma
18. Figure S1 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel
19. Tables S1-S4 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel
20. Fludarabine Exposure Impact on Safety and Efficacy of Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM)
21. Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis
22. Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL
23. Outcomes of CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma in Patients with Reduced Renal Function Including Dialysis
24. CARDIAC EVENTS AFTER ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T-CELL (IDECABTAGENE VICLEUCEL) FOR MULTIPLE MYELOMA
25. Abstract 9828: Active Surveillance of Cardiotoxicity with Cardiac Biomarkers During Chimeric Antigen Receptor T-Cell Therapy
26. Primary Progression on Frontline Therapy for Diffuse Large B-Cell Lymphoma Is Associated with a Poor Outcome Despite Subsequent CD19 Targeted CAR T-Cell Therapy
27. Outcomes of CD19 CAR T cell therapy in patients with gastrointestinal tract involvement of large B cell lymphoma
28. Advances in CAR T cell clinical development
29. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma
30. Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel
31. Regulatory challenges and considerations for the clinical application of CAR T cell therapy
32. Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel
33. NCMP-27. THE USE OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) DURING SEVERE NEUROTOXICITY AMONG THE RECIPIENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) THERAPY
34. 245 - Fludarabine Exposure Impact on Safety and Efficacy of Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM)
35. Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel
36. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma
37. Incidence and Management of Effusions during CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Receptor Therapy in B-Cell Lymphoma: A Single Institution Experience
38. Identification of Early Predictive Markers of Toxicity and Efficacy in Patients with DLBCL Treated with Axicabtagene Ciloleucel
39. Incidence and Management of Venous Thrombo-Embolism (VTE) Associated with CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Single Institution Experience
40. Hypofibrinogenemia in Patients Receiving CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Large B Cell Lymphoma: A Single Institution Experience
41. Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma
42. The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
43. Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma
44. The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell Therapy
45. NCMP-13. BRAIN MRI FINDINGS IN PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) DURING SEVERE NEUROTOXICITY
46. Prediction of toxicity in R/R DLBCL treated with Axicabtagene Clioleucel (19-28z CAR T)
47. 238 - Outcomes of CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma in Patients with Reduced Renal Function Including Dialysis
48. Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
49. Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy
50. Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.